Back to Daily DR Market Summary

StreetAccount Summary - Asian Market Preview: Nikkei Futures (0.21%), Hang Seng Futures 0.00%, ASX SPI 200 (0.93%), S&P Futures +0.13%

Oct 19 ,2026

  • Synopsis:

    • Asian markets set for a negative start to Tuesday trade. Futures signaling opening declines in Japan, Hong Kong, and South Korea. S&P 500 futures up slightly afterhours. Australian bonds weakening after Treasury yields rose along the curve overnight. FX markets steady after dollar recovered against majors. Crude little changed after climbing off earlier lows. Gold and silver steady. Bitcoin unchanged.

    • Semis/memory staged a partial bounce on Monday with SOX up 1.6%. Follows recent heavy drawdown that was put down largely to AI financing concerns sparked by blowout in CoreWeave spreads. Monday's AI bounce attributed to oversold conditions while more sell-side firms issued bullish commentary on CoreWeave. Big tech earnings this week also seen as a catalyst for a revival with results potentially shifting focus back to strength in compute demand.

    • China expected to leave 1Y and 5Y loan prime rates unchanged for a 17th consecutive month after better-than-expected Q3 GDP and September activity lessened calls for near-term policy support. Speaking at a forum on Monday, PBOC Governor Pan said central bank leaning towards overnight reverse repo rate as its benchmark rate, replacing current 7D rate. Pan added firms can also opt to use overnight repo rate as benchmark for pricing loans with LPR's relevance having waned over time.

  • Pre-open Company News:

    • 002230.CH -- Iflytek reports Q3 net income attributable CNY225.7M vs FactSet CNY81.0M [2 est, CNY35.0-127.0M]

    • 603659.CH -- Shanghai Putailai New Energy Technology reports 9M net income attributable CNY2.28B, +34% vs year-ago CNY1.70B

    • 603236.CH -- Quectel Wireless Solutions reports Q3 net income attributable CNY609.5M, +132.3% y/y

    • 4502.JP -- Takeda Pharmaceutical's Entyvio phase 4 VERDICT trial meets primary endpoint

    • 500295.IN -- Vedanta doubles zinc capacity in South Africa with $600 investment

    • 7599.JP -- IDOM Inc downgraded to equal-weight from overweight at Morgan Stanley

    • 524816.IN -- Natco Pharma, Teyro Labs launches Carboplatin Injection (generic of Paraplatin) in the US

    • 604.HK -- Shenzhen Investment reports Q3 contracted sales CNY1.81B; StreetAccount notes the year-ago figure was CNY3.03B

    • 500034.IN -- Bajaj Finance reports Q2 consolidated profit after tax INR63.67B vs StreetAccount INR64.30B

    • 605358.CH -- Hangzhou Lion Electronics reports 9M net income attributable CNY174.2M; StreetAccount notes the year-ago figure was (CNY108.0M)

    • 9887.HK -- Nanjing Leads Biolabs reports positive clinical data for cancer drugs LBL-024 and LBL-034 at ESMO

    • JPMorgan downgrades 300014.CH, 300450.CH, 3750.HK, others

    • SCC.TB -- The Siam Cement Public downgraded to equal-weight from overweight at Morgan Stanley

  • On Deck:

    • China:

      • Economic:

        • 08:00 CST: Foreign Direct Investment Y/Y

        • 09:30 CST: 1 Year Loan Prime Rate

        • 09:30 CST: 5 Year Loan Prime Rate

    • Hong Kong:

      • Earnings:

        • China Tower (788.HK)

    • Australia:

      • Earnings:

        • Challenger (CGF.AU)

    • Thailand:

      • Earnings:

        • TMBThanachart Bank Public Co. (TTB.TB)

  • Market Data:

    • Gold (Dec 26): ($6.10) or (0.15%) to $4154.00

    • WTI Crude (Nov 26): ($0.10) or (0.10%) to $103.56

    • $-¥: +0.58 or +0.37% to 158.5840

    • $-KRW: (4.43) or (0.33%) to 1330.2000

    • A$-$: +0.00 or +0.54% to 0.6984

    • $-INR: +0.02 or +0.02% to 94.9874

    • $-CNY: (0.00) or (0.01%) to 6.6901

This information and data is provided for general informational purposes only. The Bank of New York Mellon and our information suppliers do not warrant or guarantee the accuracy, timeliness or completeness of this information or data. We provide no advice nor recommendation or endorsement with respect to any company or securities. We do not undertake any obligation to update or amend this information or data. Nothing herein shall be deemed to constitute an offer to sell or a solicitation of an offer to buy securities.
Please refer to "Terms Of Use".

DEPOSITARY RECEIPTS:
NOT FDIC, STATE OR FEDERAL AGENCY INSURED
MAY LOSE VALUE
NO BANK, STATE OR FEDERAL AGENCY GUARANTEE